OncoMatch/Clinical Trials/NCT06607692
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Is NCT06607692 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Olaparib; 177Lu-DOTATATE for solid tumor cancer.
Treatment: Olaparib; 177Lu-DOTATATE — Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Glioblastoma
Neuroblastoma
Neuroendocrine Tumor
Prior therapy
Cannot have received: radiolabelled somatostatin analogue
Exception: no more than one previous treatment
Having received more than one previous treatment with other radiolabelled somatostatin analogues.
Cannot have received: long-acting somatostatin analogue
Exception: within 30 days prior the administration of 177Lu-DOTATATE
Treatment with long-acting somatostatin analogues within 30 days prior the administration of 177Lu-DOTATATE.
Lab requirements
Blood counts
Hb ≥10 g/dl (transfusion allowed up to 24h prior); WBC ≥ 2500/µL; ANC ≥ 1000/µl; Platelets ≥ 50,000/µl (no transfusion in prior ≥10 days)
Kidney function
Serum plasma creatinine ≤ 1.5 x ULN OR eGFR ≥ 60 mL/min/1.73m2 (2009-Schwartz formula)
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3.0 ULN for Gilbert's Syndrome); ALT or AST ≤ 3.0 ULN OR ≤ 5.0 ULN for patients with liver metastases; Albumin >3.0 g/dL
Adequate organ function within 28 days prior to enrolment, as defined by: Hb ≥10 g/dl... WBC ≥ 2500/µL... ANC ≥ 1000/µl; Platelets ≥ 50.000/µl... Serum plasma creatinine ≤ 1.5 x ULN OR eGFR ≥ 60 mL/min/1.73m2... Total bilirubin ≤ 1.5 x ULN. For patients with known Gilbert's Syndrome ≤ 3.0 ULN is permitted. ALT or AST ≤ 3.0 ULN OR ≤ 5.0 ULN for patients with liver metastases. Albumin >3.0 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify